- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL.
Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Xuedong Sun, M.D.
- Telefonnummer: +8615811287219
- E-mail: sunxuedong@dashengbio.com
Studiesteder
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200032
- Rekruttering
- Zhongshan Hospital, Fudan University
-
Kontakt:
- Peng Liu, M.D. & Ph.D.
- Telefonnummer: 0086-021-60267405
- E-mail: liu.peng@zs-hospital.sh.cn
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:Subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma
- Age≥18 years old,gender is not limited;
- Expected survival > 12 weeks;
- ECOG score 0-2;
- B-cell non-Hodgkin's lymphoma confirmed by cytology or histopathology according to the 2016 World Health Organization (WHO) classification and diagnostic criteria, including: diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed filter Alveolar lymphoma (TFL) and high-grade B-cell lymphoma (HGBCL);
Pathology demonstrated that B-cell non-Hodgkin's lymphoma and who meet one of the following conditions:
- Relapsed and refractory B-cell non-Hodgkin's lymphoma, after standard first-line treatment and at least 2 courses of second-line treatment without remission and relapse (the previous use of CD20-targeted drugs and anthracyclines were needed);
- Relapse of B-cell non-Hodgkin lymphoma after stem cell transplantation, regardless of previous treatments.
- The venous access required for collection can be established and leukepheresis can be carried according to the judgement of investigators, satisfying hemoglobin≥80g/L, neutrophils ≥1.0×10^9/L, platelets ≥75×10^9 / L;
- According to the Lugano 2014 criteria, there should be at least one measurable tumor lesion;
Liver, kidney and cardiopulmonary functions meet the following requirements:
- Serum creatinine≤1.5×ULN or creatinine clearance rate≥50mL/min (GockcroftGault formula);
- Cardiac ejection fraction >50%, no clinically significant pericardial effusion detected, no clinically significant pleural effusion detected;
- Baseline blood oxygen saturation>92%;
- Total bilirubin≤1.5×ULN(Gilbert syndrome≤5×ULN);
- ALT and AST≤3×ULN (AST and ALT ≤5×ULN in patients with liver metastases);
- Able to understand and sign the Informed Consent Document.
Exclusion Criteria:Any one of the following conditions cannot be selected as a subject:
- Malignant tumors other than diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL), and high-grade B-cell lymphoma (HGBCL) within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, ductal carcinoma in situ after radical resection and thyroid cancer after radical resection ;
- Subjects with positive Hepatitis B surface antigen(HBsAg) or Hepatitis B core antibody (HBcAb) and positive peripheral blood hepatitis B virus (HBV) DNA titers (higher than the upper limit of the normal range of the investigative site); Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human Immunodeficiency Viral (HIV) antibody positive; syphilis positive;
- Any uncontrolled systemic diseases, including but not limited to active infection (except for localized infection), uncontrolled angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease;
- Any other uncontrolled active disease that precludes participation in the trial;
- Any circumstances that the investigator believes will compromise the safety of the subject or interfere with the purpose of the study;
- Pregnant or lactating woman, or planned pregnancy during treatment or within 1 year after treatment, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion;
- Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment (except uncomplicated urinary tract infection or upper respiratory tract infection);
- Subjects who were receiving systemic steroid treatment within 14 days before enrollment and who were judged by the investigator to require long-term use of systemic steroid therapy during treatment (except inhalation or topical use); or subjects who received any systemic anti-tumor therapy ( except for local anti-tumor therapy) ;
- Subjects who have received CAR-T treatment or other gene-modified cell therapy before enrollment;
- Patients with symptoms of central nervous system or brain metastasis or have received treatment for central nervous system or brain metastasis (radiotherapy, surgery or other treatment) within 3 months before enrollment;
- Subjects who have a disease that affects the signing of written informed consent or who are unable to comply with research procedures; or who are unwilling or unable to comply with research requirements;
- Subjects who are considered unsuitable to participate in this trial by the investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Human CD19 Targeted T Cells Injection
Single administration:2.0×10^6
CAR+T/kg
|
A single dose of predetermined level CAR-positive T cells will be infused.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall response rate (ORR) at 3 months post infusion
Tidsramme: 3 months post infusion
|
ORR is defined as proportion of subjects who achieved Partial remission(PR) or better at 3 months (D90±7) post infusion as assessed by an independent review committee (IRC) based on Lugano 2014 criteria.
|
3 months post infusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Duration of remission (DOR) after administration
Tidsramme: 2 years post infusion
|
DOR refers to the time from the first assessment of complete response or partial response to the first assessment of disease progression or death from any cause.
|
2 years post infusion
|
Progression-free Survival (PFS) after administration
Tidsramme: 2 years post infusion
|
PFS refers to the time from the start of cell infusion to the first assessment of tumor progression or death from any cause.
|
2 years post infusion
|
Overall Survival (OS) after administration
Tidsramme: 2 years post infusion
|
OS refers to the time from cell infusion to death due to any cause.
|
2 years post infusion
|
Disease control rate (DCR)
Tidsramme: 2 years post infusion
|
The best overall response is the ratio of partial response(PR) or complete response(CR) or stable disease(SD) patients to the total number of cases.
|
2 years post infusion
|
Safety evaluation
Tidsramme: 2 years post infusion
|
The occurrence and outcome of adverse events evaluated by physical examination, laboratory examination, electrocardiogram, imaging scan, etc.
|
2 years post infusion
|
Pharmacokinetic (PK) parameters: Maximum CAR level inperipheral blood
Tidsramme: 2 years post infusion
|
The highest concentration of Human CD19 Targeted T Cells Injection amplified in peripheral blood after infusion (Cmax) .
|
2 years post infusion
|
Pharmacokinetics(PK) parameters: Time to peak CAR level in blood (Tmax)
Tidsramme: 2 years post infusion
|
The time to reach the highest concentration of Human CD19 Targeted T Cells Injection in peripheral blood after infusion (Tmax) .
|
2 years post infusion
|
Pharmacokinetics(PK) parameters: 28-day Area under the curve of the CAR level in blood(AUC0-28)
Tidsramme: 2 years post infusion
|
The 28-day area under the curve of Human CD19 Targeted T Cells Injection in peripheral blood after infusion(AUC0-28d).
|
2 years post infusion
|
Pharmacodynamic (PD) parameters
Tidsramme: 2 years post infusion
|
The clearance degree of CD19 positive B cells in peripheral blood at respective time point.
|
2 years post infusion
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HRAIN01-NHL01-Ⅱ
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med B-celle non-Hodgkins lymfom
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Ikke rekrutterer endnuLymfom | Lymfom, Non-Hodgkin | Non-Hodgkins lymfom | Non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Højgradigt B-celle lymfom | CNS lymfom | Lymfomer Non-Hodgkins B-celle | Recidiverende non-Hodgkin lymfom | Lymfom, Non-Hodgkins | Stort B-celle lymfom | Lymfom, Non-Hodgkins... og andre forhold
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringRefraktær B-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Højgradig B-celle non-Hodgkins lymfom | Mellemklasse B-celle non-Hodgkins lymfomForenede Stater
-
Caribou Biosciences, Inc.RekrutteringLymfom | Lymfom, Non-Hodgkin | B-celle lymfom | Non Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Recidiverende non-hodgkin lymfom | B-celle non-Hodgkins lymfomForenede Stater, Australien, Israel
-
University of NebraskaBristol-Myers SquibbRekrutteringFollikulært lymfom | Refraktær non-Hodgkin lymfom | Højgradigt B-celle lymfom | DLBCL - Diffust storcellet B-celle lymfom | Recidiverende non-Hodgkin lymfom | Mediastinalt stort B-cellet lymfom | Indolent B-celle non-Hodgkin lymfomForenede Stater
-
Affimed GmbHAfsluttetRefraktær B-celle non-Hodgkin lymfom | Recidiverende B-celle non-Hodgkin lymfomForenede Stater, Tjekkiet, Tyskland, Polen
-
ADC Therapeutics S.A.RekrutteringB-celle non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Recidiverende B-celle non-Hodgkin lymfomForenede Stater, Spanien, Italien, Det Forenede Kongerige, Belgien, Tjekkiet
-
CARsgen Therapeutics Co., Ltd.RenJi Hospital; First Affiliated Hospital of Zhejiang UniversityAfsluttetRefraktær B-celle non-Hodgkin lymfom | Recidiverende B-celle non-Hodgkin lymfomKina
-
Caribou Biosciences, Inc.Tilmelding efter invitationLymfom | Lymfom, Non-Hodgkin | B-celle lymfom | Non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Hæmatologisk malignitet | Recidiverende non-Hodgkin lymfom | B-celle non-Hodgkins lymfomForenede Stater
-
AstraZenecaRekrutteringEn undersøgelse af TNB-486 hos personer med recidiverende eller refraktær B-celle non-Hodgkin lymfomFollikulært lymfom | Diffust storcellet B-celle lymfom | Højgradigt B-celle lymfom | B-celle non-hodgkin lymfomKorea, Republikken, Forenede Stater, Japan, Australien, Taiwan
Kliniske forsøg med Human CD19Targeted T Cells Injection
-
CARsgen Therapeutics Co., Ltd.Aktiv, ikke rekrutterendeMyelomatoseForenede Stater, Canada
-
Ruijin HospitalShanghai Essight Bio Co.,LtdRekruttering
-
Janssen Research & Development, LLCRekrutteringMyelomatoseForenede Stater, Belgien, Kina, Israel, Holland, Spanien, Japan
-
GeneScience Pharmaceuticals Co., Ltd.The First Affiliated Hospital with Nanjing Medical University; Tongji Hospital og andre samarbejdspartnereAktiv, ikke rekrutterende
-
H. Lee Moffitt Cancer Center and Research InstituteKite, A Gilead CompanyRekrutteringStort B-celle lymfom | Recidiverende non-Hodgkin lymfomForenede Stater
-
Seattle Children's HospitalRekrutteringGliom | Ependymom | Medulloblastom, barndom | Diffus Intrinsic Pontine Gliom | Diffus midtlinjegliom | Tumor i centralnervesystemet | Kimcelletumor | Atypisk teratoide/rhabdoide tumor | Primitiv neuroektodermal tumor | Choroid Plexus Carcinom | Pineoblastom, barndomForenede Stater
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...Rekruttering
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalRekruttering
-
Assistance Publique - Hôpitaux de ParisRekrutteringHæmatologisk malignitetFrankrig
-
Assistance Publique - Hôpitaux de ParisRekrutteringPædiatriske patienter | Enhver form for svær kombineret immundefekt (SCID) | Delvis HLA-inkompatibel allogen hæmatopoietisk stamcelletransplantation (HSCT)Frankrig